Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,856
datasets available to search
ShareScore release 0.9.0
Dataset results
5,856 results for “B cell”
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
ClinicalTrials.gov study NCT02669017. IPD Sharing: NO. Countries: 3. Publications: 3.
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT02077166. IPD Sharing: YES. Countries: 4. Publications: 2.
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
ClinicalTrials.gov study NCT03088878. IPD Sharing: NO. Countries: 1. Publications: 3.
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor The
ClinicalTrials.gov study NCT02141282. IPD Sharing: YES. Countries: 1. Publications: 3.
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
ClinicalTrials.gov study NCT02332980. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
ClinicalTrials.gov study NCT01874288. IPD Sharing: NO. Countries: 1. Publications: 3.
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
ClinicalTrials.gov study NCT01397825. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
ClinicalTrials.gov study NCT00268853. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00764517. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
ClinicalTrials.gov study NCT03520920. IPD Sharing: YES. Countries: 1. Publications: 0.
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma
ClinicalTrials.gov study NCT04002401. IPD Sharing: YES. Countries: 1. Publications: 2.
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
ClinicalTrials.gov study NCT03310619. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
ClinicalTrials.gov study NCT02535364. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
ClinicalTrials.gov study NCT00622388. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lym
ClinicalTrials.gov study NCT02082977. IPD Sharing: YES. Countries: 3. Publications: 1.
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
ClinicalTrials.gov study NCT02910063. IPD Sharing: YES. Countries: 8. Publications: 1.
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00389818. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
ClinicalTrials.gov study NCT01741792. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell
ClinicalTrials.gov study NCT03677141. IPD Sharing: YES. Countries: 6. Publications: 2.
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hod
ClinicalTrials.gov study NCT01691898. IPD Sharing: Not stated. Countries: 6. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.